IMPLEMENTING THE NATIONAL OPTIMAL LUNG CANCER PATHWAY - NOVEMBER 2018 - MEMBERSHIP AND ACKNOWLEDGEMENTS

Sep 18, 2026

Upload by Noah

Implements the National Optimal Lung Cancer Pathway (NOLCP) and documents the coalition framework around the UK Lung Cancer Coalition (UKLCC). Describes the Clinical Advisory Group (CAG) composition, including senior clinicians across palliative medicine, medical oncology, respiratory medicine, pathology, nursing, and thoracic surgery, plus supporting patient and clinical groups. Sets out the UKLCC’s campaigning aims, meeting sponsorship, and financial support, then introduces the foreword, strategy context, and the rationale for adopting NOLCP to improve lung cancer outcomes in England and across devolved services.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages19

Reading Time48 min

AccessFree to download

Membership and Acknowledgements

About the UKLCC

Contact Details

Contents

Foreword

Introduction

The imperative for implementing the National Optimal Lung Cancer Pathway

Initiatives to support the implementation of NOLCP

Practical considerations when implementing the NOLCP

Conclusion

Case studies

Spotlight on optimising the Lung Cancer Pathway

Agenda and presentations

References

IMPLEMENTING THE NATIONAL OPTIMAL LUNG CANCER PATHWAY NOVEMBER 2018 MEMBERSHIP AND ACKNOWLEDGEMENTS The UKLCC’s Clinical Advisory Group (CAG) is a panel of senior clinicians, each representing particular specialities involved in the care of lung cancer patients, from the time of first suspicion of the diagnosis through to palliative care. The members of the group are: Dr Andrew Wilcock Clinical Reader in Palliative Medicine and Medical Oncology, Nottingham University Hospitals NHS Trust Ms Carol Stonham MBE Nurse Practitioner, NHS Gloucestershire CCG Dr Ian Williamson Consultant Respiratory Physician, Assistant Medical Director for Cancer Services, Aneurin Bevan University Health Board Dr Jason Lester Consultant Clinical Oncologist, Velindre Cancer Centre Professor Keith Kerr Consultant Pathologist, Aberdeen Royal Infirmary Ms Lavinia Magee Nurse Consultant, Thoracic Oncology, Papworth Hospital NHS Foundation Trust Professor Michael Lind Professor of Medical Oncology, University of Hull Dr Michael Snee Consultant Clinical Oncologist, Leeds Teaching Hospitals NHS Trust Professor Mick Peake (Chair) Clinical Director, Centre for Cancer Outcomes, Cancer Collaborative, UCLH; Emeritus Consultant and Honorary Professor of Respiratory Medicine, University of Leicester; Honorary Clinical Lead, National Cancer Registration and Analysis Service (NCRAS), Public Health England Mr Naidu Babu Consultant Thoracic Surgeon, Birmingham Heartlands Hospital Mr Richard Steyn Consultant Thoracic Surgeon; Deputy Medical Director, University Hospitals Birmingham NHS Foundation Trust; Honorary Associate Professor, University of Warwick and Chair of the UKLCC Dr Robert Rintoul Consultant Chest Physician, Department of Thoracic Oncology, Papworth Hospital NHS Foundation Trust Dr Steve Holmes General Practitioner, The Park Medical Practice, Shepton Mallet, Somerset Dr Wendy Anderson Consultant Respiratory Physician, Antrim; Northern Ireland Lung Cancer Co-Lead Miss Juliet King Consultant Thoracic Surgeon and Clinical Lead, Thoracic Surgery, Guysand St Thomas’ NHS Foundation Trust Mr Doug West Consultant Thoracic Surgeon, University Hospitals Bristol NHS Foundation Trust Professor Denis Talbot Professor of Cancer Medicine & Consultant in Medical Oncology, Oxford University Dr Ian Woolhouse Consultant Respiratory Physician, University Hospitals of Birmingham NHS Foundation Trust Mr Martin Grange Patient representative, and member of the Lung Cancer Screening Advisory Group The CAG is also supported by leading patient and clinical group members, including: — British Lung Foundation — British Thoracic Oncology Group — British Thoracic Society — Cancer Black Care — Cancer Research UK — Macmillan Cancer Support — National Lung Cancer Forum for Nurses — Primary Care Respiratory Society — Roy Castle Lung Cancer Foundation —Tenovus Cancer Care The meeting ‘Making the very best use of NHS resources and opportunities to improve outcomes for lung cancer patients in England’ was sponsored by the following: — MSD — East of England NHS Trust — UCLH NHS Foundation Trust — University Hospitals of South Manchester NHS Trust The work of the UKLCC is financially supported by the following: — Bristol-Myers Squibb — Roche Products Ltd — MSD ABOUT THE UKLCC The United Kingdom Lung Cancer Coalition (UKLCC)–the country’s largest multi-interest group in lung cancer – is a coalition of the UK’s leading lung cancer experts, senior NHS professionals, charities and healthcare companies. Through our campaigning activity we aim to: — Raise political awareness of lung cancer — Raise the general public’s awareness of lung cancer – and especially encourage earlier presentation and symptom recognition — Empower patients to take an active part in their care — Improve lung cancer services CONTACT DETAILS The UKLCC is keen to work with all interested organisat

FAQs

What is the National Optimal Lung Cancer Pathway (NOLCP) and why is it being implemented?

NOLCP is described as a practical road map and tool to improve lung cancer care. It is being prioritised so cancer alliances and services can organise facilities and people to drive measurable improvements in outcomes.

Who is included in the UKLCC Clinical Advisory Group (CAG)?

The CAG is made up of senior clinicians representing specialties involved in lung cancer care, spanning suspicion and diagnosis through palliative care. The document lists doctors, professors, nurses, and clinical leaders across multiple NHS and academic organisations.

What support, sponsorship, and financial backing are mentioned?

The document lists leading patient and clinical groups supporting the CAG. It also notes sponsorship for the meeting on improving outcomes in England and identifies organisations that financially support the work of UKLCC.

Sep 18, 2026

Upload by Noah